Journal
EMBO MOLECULAR MEDICINE
Volume 13, Issue 9, Pages -Publisher
WILEY
DOI: 10.15252/emmm.202114291
Keywords
bispecific antibodies (bsAb); malignancies; single-chain variable fragment (scFvs); tumor associate antigen; tumor-specific antigen
Categories
Funding
- Chinese Academy of Medical Sciences [2019XK320068]
- Beijing Municipal Science and Technology Commission (International Pharmaceutical Clinical Research and Development Platform 2015)
- Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (Platform Improvement of Clinical Trial Capability) [2020-I2M-2-007]
Ask authors/readers for more resources
Bispecific antibodies targeting two independent epitopes or antigens have been extensively explored in translational and clinical studies since the 1960s, with many currently being tested in clinical trials for cancer treatment. This overview discusses the targets, safety profiles, and efficacy of various types of bsAbs in clinical studies, highlighting current challenges, potential solutions, and future directions for their development in cancer treatment.
Bispecific antibodies (bsAb) that target two independent epitopes or antigens have been extensively explored in translational and clinical studies since they were first developed in the 1960s. Many bsAbs are being tested in clinical trials for treating a variety of diseases, mostly cancer. Here, we provide an overview of various types of bsAbs in clinical studies and discuss their targets, safety profiles, and efficacy. We also highlight the current challenges, potential solutions, and future directions of bsAb development for cancer treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
